mRNA for immunoproteasome subunits (No widely accepted abbreviation for the family of “mRNA for immunoproteasome subunits”. The subunit abbreviations are LMP7 (PSMB8), LMP2 (PSMB9), and MECL-1 (PSMB10))

mRNAs encoding immunoproteasome subunits (such as PSMB8/LMP7, PSMB9/LMP2, and PSMB10/MECL-1) are upregulated in response to inflammatory cytokines—most notably interferon gamma—and encode the alternative catalytic components of the immunoproteasome complex. Upon translation, these proteins replace standard proteasome subunits, modifying proteolytic activity to generate peptides optimal for MHC class I presentation and shaping the immune response, notably in defense against pathogens, tumor surveillance, and regulation of autoimmunity and inflammation. The expression of these mRNAs is a critical molecular event at the intersection of immune regulation, antigen presentation, and disease progression. However, the drug development field largely targets the protein subunits themselves, not the mRNA, making “mRNA for immunoproteasome subunits” an informational or biomarker target, rather than a canonical therapeutic target.

Other names

LMP2 (PSMB9)LMP7 (PSMB8)MECL-1 (PSMB10)β1i, β2i, β5i (“i” for “inducible”)Immunoproteasome catalytic subunit mRNAs

Inhibition of immunoproteasome catalytic activity, suppressing the generation of antigenic peptides, reducing immune responses, and modulating inflammation/cytokine secretion. In oncology, inhibition of the proteasome leads to accumulation of damaged proteins, inducing apoptosis in rapidly dividing cells